Cold Plasma Walk at ISHLT
We’re excited to be exhibiting at the ISHLT conference next week and we look forward to supporting Mr Thomas Schlöglhofer as he presents his SteriPlas Cold Plasma presentation for the management of LVAD infections during the “Bugs, Drugs, and Thugs: Fighting Infection in VADs Any Way We Can” session on Wednesday 19th April between 5:30 PM - 6:30 PM.
Due to popular demand, we will be hosting a Cold Plasma Walk session at our exhibition booth on Wednesday 19th April during the lunch break. We encourage you to visit our booth no. 416 so you can see Thomas present our medical device and explain the strong benefits it can bring to the management of LVAD infections.
Our proven and patented Cold Plasma medical device has been widely adopted as the solution for LVAD infections due to its unique physical mode of action, quick treatment times and accelerated healing with stalled infections due to biofilm all whilst protecting the patient and user from no side effects.
Contact us at info@adtecplasma.com for more information.
Day 2 of the SCTS
It's Day 2 of the Society for Cardiothoracic Surgery in GB & Ireland (SCTS) conference and we've been overwhelmed with all your interest in our Cold Plasma medical device, the SteriPlas. Visit us at booth 18 to learn more about how to bring the benefits of our medical device to your hospital.
How does the Adtec SteriPlas work so effectively?
Our patented cold plasma therapy utilises a physical mode of action approach delivered from an indirect microwave plasma source. Our cold argon plasma is an electrically charged and ionised gas that consists of charged particles, UV light and reactive oxygen and nitrogen species with the latter created as a by-product. They all work collectively to physically rupture the structure of bacteria even if they are protected within biofilm. Regardless of the type of bacteria, its resistance profile or whether they are Gram-positive or Gram-negative our cold plasma works quickly and effectively to destroy them. This has the leading advantage over conventional therapies such as antibiotics that rely on a chemical mode of action approach.
Although antibiotics have been a pivotal part of today’s medicine, they also contribute towards antimicrobial resistance rates particularly because bacteria can develop resistance such as those observed with diabetic foot ulcers that can often lead to amputations as a result.
However, as well as being fast-acting and effective, our cold plasma has shown that a primary or secondary resistance is unlikely to be developed due to its physical mode of action.
Mr Schlöglhofer to present SteriPlas at the ISHLT
Congratulations to Thomas Schlöglhofer from the Medical University of Vienna for his continued success of using our medical device to treat infections in LVAD patients. He will be presenting at The International Society for Heart and Lung Transplantation (ISHLT) conference in April to deliver the great results he has so far achieved.
His presentation, “Cold Atmospheric Plasma Therapy: A Powerful Tool for Treating Driveline Infections in Left Ventricular Assist Device Patients” will be during the “Bugs, Drugs, and Thugs: Fighting Infection in VADs Any Way We Can” Session on Wednesday 19th April between 5:30 PM - 6:30 PM.
We hope you will be there too to see him deliver his promising results.
For more information on how our medical device is fighting against multi resistant bacteria and biofilm in LVAD patients.
SteriPlas heals wounds quickly
Did you catch the leading Serbian media newspaper, Večernje Novosti, last week? Our SteriPlas was featured in the article, “Cold plasma heals wounds quickly” composed by Dr Zorić.
Dr Zoric has been using our cold plasma medical device to treat hard-to-heal and stalled wounds infected with biofilm. These problematic wounds have responded very well with our SteriPlas treatment and patients have been healed that were otherwise stalled by conventional therapies.
If you are within Serbia and interested to learn more about our medical device, contact our medical distributor Borf Health Care on info@borf.biz for more information.
Invited to speak at the ICCAC meeting on 10th January
We are honoured to be invited to speak at The International Consortium of Circulatory Assist Clinicians (ICCAC) meeting tomorrow. Our presentation will focus on the strong benefits of the Adtec SteriPlas cold plasma for the management and healing of LVAD infections. With growing interest for an alternative therapy to failing antibiotics, the SteriPlas has been storming the medical market because of its accelerated healing, safe, effective, and harmless properties all of which will be discussed tomorrow at 3.30pm (CET).
Please contact us at info@adtecplasma.com for more information.
Cold Plasma Diabetic Foot Ulcer Clinical Trial Published
Congratulations to Dr Cornelia Wiegand for her published clinical trial paper, “The efficacy of non-thermal gas plasma in the treatment of diabetic foot ulcers stalled by subclinical, biofilm-related wound infection”. This clinical trial paper features the use of our SteriPlas Cold Plasma medical device for the treatment of chronic DFUs infected with biofilm.
The parameters of this study were set much higher than a normal study, with there being a much higher standard of care given (3x per week) vs a typical outpatient setting of 1x weekly.
We wanted to show that even when chronic diabetic foot ulcers are subjected to more frequent outpatient visits with biopsies and swabs included (something not often collected during standard outpatient visits), SteriPlas Cold Plasma still prevails as the successful treatment method due to its physical mode of action and ability to kill all types of bacteria protected within biofilm.
New Wound Management of Driveline Infections with Cold Atmospheric Plasma
We’re ecstatic to see Dr Jamila Kremer’s publication, “New Wound Management of Driveline Infections with Cold Atmospheric Plasma” is now live for public viewing. The paper can be viewed here: https://doi.org/10.3390/jcdd9110405.
The use of our Adtec cold plasma medical device has greatly benefitted her LVAD infection patients treated at the University Heidelberg Hospital since 2019. The results stipulate a stronger infection management advantage over conventional therapy alone for LVAD infections. This is coupled with the benefit of our cold plasma being safe, painless, contact-free and free from side effects.
Driveline infections are the most prevalent infections and reported in up to 60% of LVAD patient cases. Infection of the LVAD system is the fourth most common cause of death within one year after implantation. Dr Kremer’s publication documents Adtec cold plasma treated patients showed a 100% survival rate.
For more information about the benefits of our Cold Plasma medical device, contact us at info@adtecplasma.com
Poster presentation at the DFSG 2022
Did you see Dr Pierides' poster presentation yesterday at the DFSG Diabetic Foot Study Group conference? The poster featured the Adtec SteriPlas success in treating chronic infected diabetic foot ulcers.
The SteriPlas replaced the use of antibiotics for these heavily infected and impacted wounds and had shown remarkable success.
TSBIWH Annual Meeting & Symposium in Taiwan
An eventful weekend for our distributor in Taiwan as they demonstrate the strong antibacterial efficacy of the Adtec SteriPlas to health care professionals at the TSBIWH 2022 Annual Meeting and Symposium.
